Wahlpflichtfach SoSe 2021 bis WiSe 2021/22

Abt. Klinische Pharmazie & Biochemie

Ansprechpartner: Dr. ir. Robin Michelet, Raum-Nr. 216,
Tel. (030) 30 838 50659, E-Mail: robin.michelet@fu-berlin.de

LITERATURE RESEARCH:
COMBINATORIAL THERAPIES FOR NON-SMALL CELL LUNG CARCINOMA WITH SENSITIZING MUTATIONS OF THE EPITHELIAL GROWTH FACTOR RECEPTOR: MECHANISMS OF RESISTANCE AND OVERCOMING THEM. [EGFR]

Beschreibung/Aufgaben

Non-small cell lung cancer is the most common type of lung cancer, amounting to almost 85% of lung carcinomas. Many (40-80%) of these are associated with overexpression of the epithelial growth factor receptor (EGFR), of which a subpopulation is treatable with EGFR-binding tyrosine kinase inhibitors such as Erlotinib. However, after initial treatment success, resistance often occurs due to a variety of mechanisms such as mutation or downregulation of the receptor. Combination therapy with other inhibitors offer an attractive solution for this resistance, as a large interaction signalling network (interactome) is associated with the EGFR and other pathways might thus be upregulated during resistance.

Lernziele/Methoden:

- Independent literature research on resistance mechanisms of EGFR-sensitive NSCLC and how to overcome them with combinatorial therapies
- Summarising of the literature research in a report and presentation of the results

Beginn: as per agreement

Voraussetzungen:	Interest in combinatorial therapies, oncology, Scientific reading and writing skills
2 Studierende	(Studierende des 7. und 8. Semesters werden bevorzugt)
Anmeldung:	Bis 24.05.2021 per E-Mail bei Frau Prof. Dr. Charlotte Kloft (charlotte.kloft@fu-berlin.de, CC an ingo.siebenbrodt@fu-berlin.de) mit kurzer Bewerbung einschl. Darlegung der Motivation für das Wahlpflichtthema. **EGFR**

2020-10-27 gez. Prof. Dr. Ch. Kloft